Drug Profile
Research programme: protozoal infection therapeutics - Drugs for Neglected Diseases/Pfizer
Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Drugs for Neglected Diseases Initiative Foundation; Pfizer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis; Chagas disease; Visceral leishmaniasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in African trypanosomiasis in Australia
- 16 Jul 2016 No recent reports of development identified for research development in visceral leishmaniasis in South Korea
- 19 Nov 2009 Early research in African trypanosomiasis in Australia (unspecified route)